Amp Volatility Score
Catalyst Info & Data Links
TITLE: Rucaparib(Rubraca®) for Prostate Cancer - Phase 3
ClinicalTrial.gov (NCT02975934): A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
WHAT IS THE NEXT CATALYST EVENT?
Completion of Enrollment
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
08-26-2020 FDA Approves FoundationOne® Liquid CDx To Serve As Rubraca® (Rucaparib) Companion Diagnostic To Identify Eligible Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC)
08-17-2020 Journal Of Clinical Oncology Publishes Additional Data From Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (Rucaparib) For The Treatment Of MCRPC In Patients With BRCA1/2 Gene Mutations
05-15-2020 Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
MECHANISM OF ACTION
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents.
Updated by JM
CLVS, Clovis Oncology, Prostate Cancer, Ovarian, Rucaparib(Rubraca®)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post